Welcome to the international HTA database

Showing [16733 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2023	NIHR Health Technology Assessment programme	Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies
2023	Health Information and Quality Authority (HIQA)	A rapid health technology assessment of gene expression profiling tests for guiding the use of adjuvant chemotherapy in early-stage invasive breast cancer
2023	NIHR Health Technology Assessment programme	Antibiotics for lower respiratory tract infection in children presenting in primary care: ARTIC-PC RCT
2023	Norwegian Institute of Public Health (NIPH)	Transcutaneous non-invasive vagus nerve stimulation (gammaCore) for the treatment of cluster headache: A single technology assessment
2023	NIHR Health Services and Delivery Research programme	Factors which facilitate or impede patient engagement with pulmonary and cardiac rehabilitation: a rapid evaluation mapping review
2023	Norwegian Institute of Public Health (NIPH)	Stockholm3 test to estimate the risk of prostate cancer: a single technology assessment
2023	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	The clinical effectiveness of denosumab (Prolia) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
2023	NIHR Health Services and Delivery Research programme	A multimethod study of NHS 111 online
2023	NIHR Health Services and Delivery Research programme	Thinking ahead about medical treatments in advanced illness: a qualitative study of barriers and enablers in end-of-life care planning with patients and families from ethnically diverse backgrounds
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Eladocagene exuparvovec (Aromatic-L-amino acid decarboxylase (AADC) deficiency, ≥ 18 months)]
2023	NIHR Health Services and Delivery Research programme	Towards achieving interorganisational collaboration between health-care providers: a realist evidence synthesis
2023	NIHR Health Services and Delivery Research programme	Early evaluation of the Children and Young People's Mental Health Trailblazer programme: a rapid mixed-methods study
2023	NIHR Health Services and Delivery Research programme	New and emerging technology for adult social care - the example of home sensors with artificial intelligence (AI) technology
2023	NIHR Health Services and Delivery Research programme	Youth violence intervention programme for vulnerable young people attending emergency departments in London: a rapid evaluation
2023	NIHR Health Services and Delivery Research programme	The effects of computerised decision support systems on nursing and allied health professional performance and patient outcomes: a systematic review and user contextualisation
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Percutaneous mitral valve repair with a clip device in patients with mitral regurgitation. Update 2023
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Allogeneic mesenchymal stem cells for Crohn's disease-associated complex perianal fistulas. Update 2023
2023	Austrian Institute for Health Technology Assessment (AIHTA)	177Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer: Update 2023 - systematic review
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Percutaneous aspiration thrombectomy for pulmonary embolism
2023	Agency for Care Effectiveness (ACE)	Daratumumab for treating newly diagnosed light chain (AL) amyloidosis
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Transcranial magnetic resonance-guided high-intensity focused ultrasound treatment in patients with drug-resistant essential tremor
2023	Institute for Clinical and Economic Review (ICER)	Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value
2023	Agency for Care Effectiveness (ACE)	Inhaled corticosteroids with long acting beta-2 agonists for treating asthma
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Bleomycin electrosclerotherapy for vascular anomalies
2023	Institute for Clinical and Economic Review (ICER)	Lecanemab for early Alzheimer’s disease
2023	Agency for Care Effectiveness (ACE)	Palivizumab for preventing serious lower respiratory tract disease caused by respiratory syncytial virus
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Electrical auricular vagus nerve stimulation for pain
2023	Institute for Clinical and Economic Review (ICER)	Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH)
2023	Agency for Care Effectiveness (ACE)	Echinocandins for treating invasive candidiasis
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Nurse-driven protocols for antibiotic initiation in febrile neutropenia
2023	Institute for Clinical and Economic Review (ICER)	Gene therapies for sickle cell disease
2023	Institute for Clinical and Economic Review (ICER)	Atidarsagene autotemcel for metachromatic leukodystrophy
2023	Malaysian Health Technology Assessment (MaHTAS)	Bio-electrical impedance analysis for the assessment of sarcopenia in elderly
2023	Malaysian Health Technology Assessment (MaHTAS)	Nasojejunal tube in upper gastrointestinal conditions
2023	Adelaide Health Technology Assessment (AHTA)	Abdominal MRI for rare genetic conditions associated with increased risk of renal tumours
2023	NIHR Health Technology Assessment programme	Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation
2023	Malaysian Health Technology Assessment (MaHTAS)	Human skin allograft for burns
2023	Health Information and Quality Authority (HIQA)	Lutetium oxodotreotide for the treatment of metastatic or inoperable gastroenteropancreatic neuroendocrine tumours (GEP-NETs): evidence synthesis to support a generic justification decision
2023	Health Information and Quality Authority (HIQA)	Rapid health technology assessment of the extension of the seasonal influenza vaccination programme to include those aged 50 to 64 years (general population)
2023	Malaysian Health Technology Assessment (MaHTAS)	Negative pressure wound therapy
2023	Health Information and Quality Authority (HIQA)	A slot-scanning, biplanar, digital X-ray imaging system for the evaluation and monitoring of orthopaedic conditions: evidence synthesis to support a generic justification decision
2023	Health Information and Quality Authority (HIQA)	Analysis of public consultation surveys to inform the work of the Public Health Reform Expert Advisory Group [protocols and report]
2023	Health Information and Quality Authority (HIQA)	Interventions to improve long COVID symptoms: a systematic review
2023	Health Information and Quality Authority (HIQA)	Methods for generic justification of new practices in ionising radiation
2023	Health Information and Quality Authority (HIQA)	Expansion of the childhood immunisation schedule to include varicella (chickenpox) vaccination: health technology assessment
2023	Health Technology Wales (HTW)	Control contact lenses and spectacles for the treatment of myopia in children
2023	Scottish Health Technologies Group (SHTG)	Priorities for the north imaging alliance
2023	Scottish Health Technologies Group (SHTG)	The cost-effectiveness of the Scottish Hip Fracture Audit
2023	Scottish Health Technologies Group (SHTG)	Capsule sponge technologies for the detection of Barrett’s oesophagus and early stage oesophageal cancer
2023	WorkSafeBC	Causal association between SARS-Cov-2 infection and the development of trigeminal neuralgia
2023	Scottish Health Technologies Group (SHTG)	Technology-enabled theatre scheduling systems
2023	WorkSafeBC	Causal association between carpal tunnel release surgery and trigger finger
2023	Scottish Health Technologies Group (SHTG)	Digital prevention programme for people at risk of type 2 diabetes
2023	National Institute for Health and Care Excellence (NICE)	Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes. NICE technology appraisal guidance 943
2023	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Trends in utilisation of ultrasound by older Australians (2010-2019)
2023	WorkSafeBC	Platelet rich plasma in treating (recurrent) anterior shoulder dislocation
2023	National Institute for Health and Care Excellence (NICE)	Empagliflozin for treating chronic kidney disease. NICE technology appraisal guidance 942
2023	WorkSafeBC	Esketamine as treatment for depression and PTSD
2023	National Institute for Health and Care Excellence (NICE)	Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal). NICE technology appraisal guidance 941
2023	WorkSafeBC	Botulinum toxin as treatment for neck strains
2023	National Institute for Health and Care Excellence (NICE)	Ravulizumab for treating generalised myasthenia gravis (terminated appraisal). NICE technology appraisal guidance 940
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Sutimlimab (cold agglutinin disease)]
2023	WorkSafeBC	Migraines and the (Moderna) COVID-19 vaccine
2023	National Institute for Health and Care Excellence (NICE)	Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer. NICE technology appraisal guidance 939
2023	WorkSafeBC	Causal association between COVID-19 infection and irritable larynx syndrome
2023	National Institute for Health and Care Excellence (NICE)	Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal). NICE technology appraisal guidance 938
2023	WorkSafeBC	Efficacy of under-mask beard covers in quantitative fit testing of tight-fitting disposable respirators
2023	WorkSafeBC	Platelet rich plasma as treatment for medial epicondylitis
2023	National Institute for Health and Care Excellence (NICE)	Targeted-release budesonide for treating primary IgA nephropathy. NICE technology appraisal guidance 937
2023	WorkSafeBC	Flotation therapy as treatment for concussions
2023	WorkSafeBC	Myalgic encephalomyelitis/chronic fatigue syndrome associated with mRNA COVID-19 vaccination
2022	Austrian Institute for Health Technology Assessment (AIHTA)	ATMPs and gene therapies in development. Horizon scanning – update 2022
2022	Health Information and Quality Authority (HIQA)	High level review of configuration and reform of public health systems in selected countries
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Peer support programs for youth mental health
2022	NIHR Health Technology Assessment programme	Multicentre UK study of the acetylcholinesterase inhibitor donepezil in early dementia associated with Parkinson's disease (MUSTARDD-PD)
2022	Center for Drug Evaluation (CDE)	The reimbursement coverage decisions and pricing rules for medical devices in Taiwan
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Internet-delivered cognitive behavioural therapy in the treatment of chronic non-cancer pain
2022	NIHR Health Technology Assessment programme	A pragmatic randomised controlled trial and economic evaluation of family therapy vs. treatment as usual for young people seen after second or subsequent episodes of self-harm: the Self-Harm Intervention - Family Therapy (SHIFT) trial
2022	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Promoting mental well-being in children and adolescents]
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Patient bias against healthcare providers
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Dapagliflozin for chronic kidney disease
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Systemic thrombolysis by alteplase for acute ischemic stroke
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Systemic thrombolysis and endovascular therapy for large vessel occlusion acute ischemic stroke
2022	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Psychological Treatment for Postpartum Depression]
2022	NIHR Health Technology Assessment programme	Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT
2022	Health Information and Quality Authority (HIQA)	Catalogue of institutions undertaking COVID-19 horizon scanning
2022	Institute for Clinical and Economic Review (ICER)	Medications for obesity management: effectiveness and value
2022	Health Information and Quality Authority (HIQA)	Planned public health measures and strategies to limit the impact of COVID-19 surges: an international review
2022	Institute for Clinical and Economic Review (ICER)	AMX0035 and oral edaravone for amyotrophic lateral sclerosis
2022	National Institute for Health and Care Excellence (NICE)	Cabotegravir with rilpivirine for treating HIV-1. NICE technology appraisal guidance 757
2022	Ontario Health	First-trimester screening program for the risk of pre-eclampsia using a multiple-marker algorithm: a health technology assessment
2022	Institute for Clinical and Economic Review (ICER)	Novel agents to prevent chemotherapy-induced neutropenia and other myelosuppressive effects [updated Sept 29, 2023]
2022	National Institute for Health and Care Excellence (NICE)	Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy. NICE technology appraisal guidance 758
2022	National Institute for Health and Care Excellence (NICE)	Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 760
2022	NIHR Health Technology Assessment programme	Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling
2022	National Institute for Health and Care Excellence (NICE)	Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection. NICE technology appraisal guidance 761
2022	Center for Drug Evaluation (CDE)	First-line treatment and overall survival in EGFR mutation-positive advanced non-small cell lung cancer: a national cohort study
2022	National Institute for Health and Care Excellence (NICE)	Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal). NICE technology appraisal guidance 762
2022	Austrian Institute for Health Technology Assessment (AIHTA)	Percutaneous coronary interventions (PCI) for chronic total occlusion (CTO). Update 2022
2022	National Institute for Health and Care Excellence (NICE)	Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable. NICE technology appraisal guidance 763